AEONHIGH SIGNALRISK10-K

AEON faces potential NYSE American delisting while experiencing dramatic swings in its financial position, including substantially reduced R&D spending and meaningfully increased total liabilities.

The addition of specific delisting risk language indicates the company may be struggling with exchange listing requirements, which could severely impact liquidity and capital raising ability. The company has also shifted its positioning from a clinical-stage developer to focusing on biosimilar development, suggesting a strategic pivot that may reflect changing business priorities or regulatory challenges.

Comparing 2026-03-30 vs 2025-03-24View on EDGAR →
FINANCIAL ANALYSIS

AEON's financial profile shows mixed signals with improved operating cash flow burn (reducing from $20.3M to $17.3M in outflows) but concerning balance sheet deterioration as total liabilities grew substantially to $60.6M. R&D expenses declined dramatically from $14.2M to $4.1M, suggesting either completed development phases or cost-cutting measures, while the company's asset base expanded modestly. The sharp reduction in capital expenditures and R&D spending alongside increased liabilities suggests potential liquidity constraints forcing operational adjustments.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-98.7%
$306K→$4K

Capex reduced 98.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
+91.1%
$31.7M→$60.6M

Liabilities grew 91.1% — significant increase in debt or obligations, assess impact on financial flexibility.

Total Assets
Balance Sheet
+77%
$3.1M→$5.6M

Asset base grew 77% — expansion through organic growth, acquisitions, or capital deployment.

R&D Expense
P&L
-71.1%
$14.2M→$4.1M

R&D spending cut 71.1% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
-51.3%
$14.1M→$6.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Operating Cash Flow
Cash Flow
+14.7%
-$20.3M→-$17.3M

Operating cash flow grew 14.7% — strong conversion of earnings to cash, healthy business fundamentals.

SG&A Expense
P&L
-10.5%
$13.6M→$12.2M

SG&A reduced 10.5% — improved cost efficiency or headcount reduction improving operating margins.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-24
ADDED
As of March 23, 2026, there were 25,303,058 of the registrant s shares of Class A common stock, $0.0001 par value per share, outstanding.
If we fail to regain or maintain compliance with the continued listing requirements of the NYSE American, our common stock may be delisted, which could significantly reduce its liquidity, market visibility, and trading volume, increase price volatility, and negatively impact our ability to raise capital on favorable terms.
Such a delisting could materially adversely affect the market price of our common stock and our overall financial condition.
Business AEON is a biopharmaceutical company advancing its proprietary botulinum toxin complex ABP-450 as a biosimilar to Botox (onabotulinumtoxinA) with the goal of achieving full-label United States ( U.S.
Overview We are a biopharmaceutical company focused on developing ABP-450 as a biosimilar to Botox (onabotulinumtoxinA) for therapeutic indications.
+7 more — sign up free →
REMOVED
As of March 21, 2025, there were 10,532,802 of the registrant s shares of Class A common stock, $0.0001 par value per share, outstanding.
(the Daewoong Agreement ); AEON s ability to compete effectively with existing competitors and new market entrants; potential effects of extensive government regulation; AEON s future financial performance and capital requirements; AEON s ability to implement and maintain effective internal controls; the impact of supply chain disruptions; and the impact of macroeconomic developments beyond our control, such as health epidemics or pandemics, macro-economic uncertainties, social unrest, hostilities, natural disasters or other catastrophic events, on AEON s business.
( AEON ) is a biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection ( ABP-450 ), for debilitating medical conditions.
and its consolidated subsidiaries prior to the Merger ( Old AEON or the Predecessor ) and to AEON Biopharma, Inc.
Overview We are a clinical stage biopharmaceutical company focused on developing our botulinum toxin complex, prabotulinumtoxinA injection ( ABP-450 ), for debilitating medical conditions, with an initial focus on the neurosciences market.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →